The piggyBac transposon is an integrating non-viral gene transfer vector that enhances the efficiency of GDEPT

Cell Biology International

Volumn 33, Issue 4, 2009, Pages 509-515

  Kang, Yu ^a,b   Zhang, Xiao Yan ^a,b   Jiang, Wei ^a,b   Wu, Chao Qun ^c   Chen, Chun Mei ^c   Gu, Jian Ren ^d   Zheng, Yu Fang ^c   Xu, Cong Jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI CANCER INSTITUTE   (China)

Author keywords

GDEPT; Gene delivery; Non viral vector; Ovarian cancer; PiggyBac (PB) transposon; Suicide gene

Indexed keywords

ANTINEOPLASTIC AGENT; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; PRODRUG; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CARCINOMA CELL; CELL ASSAY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPEN READING FRAME; OVARY ADENOCARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REPORTER GENE; TRANSPOSON; VIRUS GENE; WESTERN BLOTTING;

ADENOCARCINOMA; CELL LINE, TUMOR; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; LUMINESCENT PROTEINS; OVARIAN NEOPLASMS; PRODRUGS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; TRANSFECTION;

SIMPLEXVIRUS; VERTEBRATA;

EID: 63349088595     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2009.01.017     Document Type: Article

References (26)

1. Baum C., and Fehse B. Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Curr Opin Mol Ther 5 (2003) 458-462
2. Ding S., Wu X., Li G., Han M., Zhuang Y., and Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122 (2005) 473-483
3. Fillat C., Carrio M., Cascante A., and Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3 (2003) 13-26
4. Freytag S.O., Movsas B., Aref I., Stricker H., Peabody J., Pegg J., et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15 (2007) 1016-1023
5. Graham A., Walker R., Baird P., Hahn C.N., and Fazakerley J.K. CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity. Mol Ther 13 (2006) 631-635
6. Hackett C.S., Geurts A.M., and Hackett P.B. Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy. Genome Biol 8 Suppl. 1 (2007) S12
7. Hedley D., Ogilvie L., and Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer 7 (2007) 870-879
8. Huang X., Wilber A.C., Bao L., Tuong D., Tolar J., Orchard P.J., et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 107 (2006) 483-491
9. Ivics Z., and Izsvak Z. Transposons for gene therapy!. Curr Gene Ther 6 (2006) 593-607
10. Kay M.A., Glorioso J.C., and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7 (2001) 33-40
11. Kumar M., Bradow B.P., and Zimmerberg J. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. Hum Gene Ther 14 (2003) 67-77
12. Marshall E. Gene therapy on trial. Science 288 (2000) 951-957
13. Muruve D.A., Barnes M.J., Stillman I.E., and Libermann T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10 (1999) 965-976
14. Nawa A., Tanino T., Luo C., Iwaki M., Kajiyama H., Shibata K., et al. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?. Anti Cancer Agents Med Chem 8 (2008) 232-239
15. Nishikawa M., and Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12 (2001) 861-870
16. Okada T., Caplen N.J., Ramsey W.J., Onodera M., Shimazaki K., Nomoto T., et al. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo. J Gene Med 6 (2004) 288-299
17. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
18. Portsmouth D., Hlavaty J., and Renner M. Suicide genes for cancer therapy. Mol Aspects Med 28 (2007) 4-41
19. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11 (2000) 2389-2401
20. Reeves L., Smucker P., and Cornetta K. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene Ther 11 (2000) 2093-2103
21. Singh S., Cunningham C., Buchanan A., Jolly D.J., and Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol Ther 4 (2001) 157-160
22. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11 (2005) 7444-7453
23. Wilson M.H., Coates C.J., and George Jr. A.L. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 15 (2007) 139-145
24. Winston D.J., Wirin D., Shaked A., and Busuttil R.W. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346 (1995) 69-74 10.1016/S0140-6736(95)92110-9
25. Wolf J.K., and Jenkins A.D. Gene therapy for ovarian cancer (review). Int J Oncol 21 (2002) 461-468
26. Wu S.C., Meir Y.J., Coates C.J., Handler A.M., Pelczar P., Moisyadi S., et al. PiggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA 103 (2006) 15008-15013